Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia plc

AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

single-target-small-molecules

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster.

Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success.

Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. 

By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Bill & Melinda Gates Foundation

Sanofi

SoftBank Vision Fund

Marshall Wace

BlackRock

Bristol Myers Squibb

GT Healthcare Capital Partners

Hongyou Investment

Novo Holdings

Casdin Capital

Pivotal bioVenture Partners

Mubadala

Exscientia

ICYMI: Watch Michael Krams, Chief Quantitative Medicine Officer and other veteran drug developers discuss best practices in designing clinical trial protocols in the “Trial Protocol Design Do's And Don'ts” webinar https://lnkd.in/ebF3wfa7 
#clinicaltrials #webinar

Dan Woodward, Cheminformatics Research Scientist, shared some great insights on Coverage Score, our active learning method to efficiently sample a given chemical space, today at the Ninth Joint Sheffield Conference on Chemoinformatics. 

To learn more about Coverage Score and how it may lead to faster model improvement and shorter hit to candidate ID, read Dan’s JCIM paper fully detailing the method: https://lnkd.in/eZXPxJE3

#research #learning #activelearning #drugdiscovery #drugdevelopment

Exciting opportunity to start your research career in structural bioinformatics, in an industry-funded collaboration between Exscientia and the University of York. 
#bioinformatics #structuralbioinformatics #phd #phdposition

Watch Garry Pairaudeau, CTO discuss how, at Exscientia, we’re transforming drug discovery using our AI-driven platform. 
https://lnkd.in/gyxqk9KD
#drugdiscovery #ai

There’s still time to register for next week’s Amazon Web Services (AWS)  event to hear from Tjelvar Olsson, Senior DevOps Engineer on how we’re using AWS as part of how we accelerate our drug discovery method development.

#aws #cloud #drugdiscovery

If you’re looking to learn more about the best practices in designing clinical trial protocols, don’t miss the webinar this week featuring insight from veteran drug developers including our own Michael Krams, Chief Quantitative Medicine Officer.
#clinicaltrials #webinar

Congratulations to Gregory Vladimer, VP Translational Research who has been recognised as an LGBTQ+ biopharma leader by Endpoints News. Greg has helped change the way the cancer drug development field looks at preclinical translational models, among other important advances.

Read more below about Greg and the other renowned scientists leading the way for LGBTQ+ inclusion in the drug development industry.

Professor Andrew Hopkins, Exscientia’s founder and CEO, is presenting as part of Institute for Population and Precision Health at the University of Chicago's Distinguished Seminar Series next week.

Register now to find out how Exscientia’s scientists and technology experts are tailoring and integrating #AI to facilitate the speed and efficiencies of innovative drug design, discovery and development and to also improve the quality and precision-targeting of future therapies. https://lnkd.in/eMvZ8_Pp

#drugdesign, #drugdiscovery

G. Su Jerwood, Gemma Perry and Garry Pairaudeau provided fantastic insights at SLAS Europe this week, showcasing Exscientia’s development of computer-aided biology approaches - combining design of experiments and automation for biochemical assay optimisation. 

Download our poster to learn more: https://lnkd.in/evuqcsEP

#slaseurope2023 #automation #designofexperiments

Today, we announced our 1Q 2023 financial results and provided a business update. Visit our website to listen to today’s $EXAI webcast at 1:30 p.m. BST / 8:30 a.m. ET 
https://lnkd.in/e_vRk4W7

Metric
Company Name	Exscientia plc	AMPLY Discovery
Symbol	EXAI
MSH ID	AI:EXSCIENTIA	COM:AMPLYDISCOVERY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	GB	GB
Stage
Employee Count	483	7
Website	exscientia.ai	amplydiscovery.com
LinkedIn
Founders

Metric
Market Cap	723.67M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	24.96M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-28.48M
EBITDA	-204.14M
Operating Income	-223.52M
Net Income	-181.44M
EPS	-1.46
Diluted EPS	-1.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.28
Operating Profit Margin	-7.14
EBITDA Margin	-8.18
Net Profit Margin	-5.88
Return on Equity	-0.33
Return on Assets	-0.27
Return on Capital Employed	-0.38

AI:EXSCIENTIA

Exscientia plc

Last Close

4.84

19/11 21:00

Market Cap

723.67M

Beta: -

Volume Today

1.45M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.75
P/B Ratio	1.45
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	30.42
EV Multiple	-4.45

Metric
Days Sales Outstanding	992.91
Days Payables Outstanding	114.19
Days Inventory Outstanding	0.00
Operating Cycle	992.91
Cash Conversion Cycle	878.72
Asset Turnover	0.05

Metric
Operating Cash Flow	-146.19M
Free Cash Flow	-179.32M
Cash Flow to Debt	-4.68
Operating Cash Flow/Sales	-4.76
Free Cash Flow Yield	-0.37

Metric
Cash & Equivalents	330.76M
Accounts Receivable	-8.67M
Inventory	1
Goodwill	7.89M
Debt to Capitalization	0.07
Debt to Assets	0.03
Current Ratio	6.67
Quick Ratio	6.58

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.18
R&D to Revenue	5.40
SG&A to Revenue	1.69